Femasys Inc. (NASDAQ: FEMY) has initiated patient enrollment in the FINALE pivotal clinical trial evaluating FemBloc, a non-surgical permanent birth ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE